Indications
Vyepti is indicated for the prophylaxis of migraine in adults who have at least 4 migraine days per month.
Composition
- Active substance
- Eptinezumab
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Vyepti
- Active substance
- Eptinezumab
- ATC code
- N02CD
- Group
- Nervous system
- Therapeutic area
- Migraine Disorders
- Marketing authorisation holder
- H. Lundbeck A/S
- Status
- Authorised
- EU authorisation
- 24 Jan 2022
- EMA product number
- EMEA/H/C/005287